BR112014004620B1 - uso do ‘peptídeo ativador da adenilato ciclase de pituitária’, composição de vacina e combinação de vacina - Google Patents
uso do ‘peptídeo ativador da adenilato ciclase de pituitária’, composição de vacina e combinação de vacina Download PDFInfo
- Publication number
- BR112014004620B1 BR112014004620B1 BR112014004620-4A BR112014004620A BR112014004620B1 BR 112014004620 B1 BR112014004620 B1 BR 112014004620B1 BR 112014004620 A BR112014004620 A BR 112014004620A BR 112014004620 B1 BR112014004620 B1 BR 112014004620B1
- Authority
- BR
- Brazil
- Prior art keywords
- pacap
- fish
- vaccine
- fact
- group
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 58
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 102000030621 adenylate cyclase Human genes 0.000 title claims abstract description 12
- 108060000200 adenylate cyclase Proteins 0.000 title claims abstract description 12
- 230000001817 pituitary effect Effects 0.000 title claims abstract description 11
- 230000003213 activating effect Effects 0.000 title claims description 8
- 108091007433 antigens Proteins 0.000 claims abstract description 37
- 102000036639 antigens Human genes 0.000 claims abstract description 37
- 239000000427 antigen Substances 0.000 claims abstract description 36
- 239000002671 adjuvant Substances 0.000 claims abstract description 30
- 238000007654 immersion Methods 0.000 claims abstract description 15
- 230000028993 immune response Effects 0.000 claims abstract description 15
- 241000700605 Viruses Species 0.000 claims abstract description 14
- 239000007924 injection Substances 0.000 claims abstract description 10
- 238000002347 injection Methods 0.000 claims abstract description 10
- 239000012678 infectious agent Substances 0.000 claims abstract description 9
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 244000078703 ectoparasite Species 0.000 claims abstract description 4
- 241000251468 Actinopterygii Species 0.000 claims description 74
- 238000002649 immunization Methods 0.000 claims description 17
- 230000003053 immunization Effects 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108020004511 Recombinant DNA Proteins 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 235000014105 formulated food Nutrition 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 abstract description 8
- 230000004044 response Effects 0.000 abstract description 6
- 230000001965 increasing effect Effects 0.000 abstract description 5
- 101150060255 MZB1 gene Proteins 0.000 abstract description 4
- 101100462550 Mus musculus Adcyap1 gene Proteins 0.000 abstract description 4
- 229940126513 cyclase activator Drugs 0.000 abstract 2
- 235000019688 fish Nutrition 0.000 description 88
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 24
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 23
- 239000002953 phosphate buffered saline Substances 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 210000000265 leukocyte Anatomy 0.000 description 17
- 108010041986 DNA Vaccines Proteins 0.000 description 14
- 229940021995 DNA vaccine Drugs 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 244000045947 parasite Species 0.000 description 13
- 241000607528 Aeromonas hydrophila Species 0.000 description 11
- 241000277275 Oncorhynchus mykiss Species 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 101710154606 Hemagglutinin Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 9
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 9
- 101710176177 Protein A56 Proteins 0.000 description 9
- 230000036755 cellular response Effects 0.000 description 9
- 239000000185 hemagglutinin Substances 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 239000013642 negative control Substances 0.000 description 8
- 241000252233 Cyprinus carpio Species 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 7
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 7
- 102000003812 Interleukin-15 Human genes 0.000 description 7
- 108090000172 Interleukin-15 Proteins 0.000 description 7
- 235000013330 chicken meat Nutrition 0.000 description 7
- 238000011260 co-administration Methods 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 206010061217 Infestation Diseases 0.000 description 6
- 241000711825 Viral hemorrhagic septicemia virus Species 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 241000248482 Ichthyophthirius multifiliis Species 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 235000015170 shellfish Nutrition 0.000 description 5
- 241000721191 Clarias gariepinus Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102100037907 High mobility group protein B1 Human genes 0.000 description 4
- 241000252498 Ictalurus punctatus Species 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000240 adjuvant effect Effects 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000002516 postimmunization Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102000008482 12E7 Antigen Human genes 0.000 description 3
- 108010020567 12E7 Antigen Proteins 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241001611004 Caligus rogercresseyi Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 3
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 241000277289 Salmo salar Species 0.000 description 3
- 241000277331 Salmonidae Species 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 3
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000008348 humoral response Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 241000546112 Infectious salmon anemia virus Species 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 101900220844 Viral hemorrhagic septicemia virus Spike glycoprotein Proteins 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000004523 agglutinating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000006041 cell recruitment Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XULKGRJEOPRYTO-UHFFFAOYSA-N vip-pacap Chemical compound C=1C=C(O)C=CC=1CC(C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(N)=O)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)C(C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(N)CC=1N=CNC=1)C(C)C)C(C)O)CC1=CC=C(O)C=C1 XULKGRJEOPRYTO-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 241000252231 Cyprinus Species 0.000 description 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 description 1
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 1
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229960005552 PAC-1 Drugs 0.000 description 1
- 108020000631 PAC1 receptors Proteins 0.000 description 1
- 206010058096 Pancreatic necrosis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102000005737 Type I Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 description 1
- 101150024766 VP1 gene Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000002260 hypophysiotrophic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2011000167A CU24075B1 (es) | 2011-08-26 | 2011-08-26 | Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular. |
| PCT/CU2012/000004 WO2013029570A1 (es) | 2011-08-26 | 2012-08-24 | Uso del pacap como adyuvante molecular para vacunas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014004620A2 BR112014004620A2 (pt) | 2017-03-21 |
| BR112014004620B1 true BR112014004620B1 (pt) | 2019-10-29 |
Family
ID=47046313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014004620-4A BR112014004620B1 (pt) | 2011-08-26 | 2012-08-24 | uso do ‘peptídeo ativador da adenilato ciclase de pituitária’, composição de vacina e combinação de vacina |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9549977B2 (https=) |
| EP (1) | EP2749291B1 (https=) |
| JP (1) | JP6077541B2 (https=) |
| KR (1) | KR101857705B1 (https=) |
| CN (1) | CN103874510A (https=) |
| AU (1) | AU2012303887B2 (https=) |
| BR (1) | BR112014004620B1 (https=) |
| CA (1) | CA2844898C (https=) |
| CL (1) | CL2014000386A1 (https=) |
| CU (1) | CU24075B1 (https=) |
| ES (1) | ES2648337T3 (https=) |
| MX (1) | MX351725B (https=) |
| MY (1) | MY191697A (https=) |
| NO (1) | NO2749291T3 (https=) |
| PH (1) | PH12014500397B1 (https=) |
| PT (1) | PT2749291T (https=) |
| RU (1) | RU2580294C2 (https=) |
| SG (1) | SG11201400215SA (https=) |
| WO (1) | WO2013029570A1 (https=) |
| ZA (1) | ZA201401271B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190060057A (ko) | 2017-11-24 | 2019-06-03 | 유병희 | 웰빙 무드등 |
| US20220202905A1 (en) * | 2019-05-14 | 2022-06-30 | Senju Pharmaceutical Co., Ltd. | Composition for preventing or treating neurotrophic keratitis which contains pacap peptide or stabilized pacap peptide |
| CN117617183B (zh) * | 2023-11-29 | 2025-09-05 | 中国医学科学院医药生物技术研究所 | 突变体斑马鱼在制备凝血功能障碍疾病的动物模型中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE65568B1 (en) * | 1990-10-22 | 1995-11-01 | Unilever Plc | Vaccine compositions for fish |
| CA2379604A1 (en) * | 1999-09-28 | 2001-04-05 | Bayer Corporation | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use |
| GB0427267D0 (en) * | 2004-12-13 | 2005-01-12 | Maria Teresa De Magistris | Peptide adjuvants |
| CU23557A1 (es) | 2005-11-22 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Neuropéptidos para el cultivo de organismos acuáticos |
| CA2779496A1 (en) * | 2009-11-02 | 2011-05-05 | The Administrators Of The Tulane Educational Fund | Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
| CN103255089B (zh) * | 2013-05-03 | 2015-08-05 | 中国水产科学研究院黄海水产研究所 | 一株强毒迟缓爱德华氏菌疫苗株及其应用 |
-
2011
- 2011-08-26 CU CU2011000167A patent/CU24075B1/es active IP Right Grant
-
2012
- 2012-08-24 MX MX2014002214A patent/MX351725B/es active IP Right Grant
- 2012-08-24 MY MYPI2014700419A patent/MY191697A/en unknown
- 2012-08-24 WO PCT/CU2012/000004 patent/WO2013029570A1/es not_active Ceased
- 2012-08-24 AU AU2012303887A patent/AU2012303887B2/en not_active Ceased
- 2012-08-24 JP JP2014526385A patent/JP6077541B2/ja active Active
- 2012-08-24 CN CN201280041829.5A patent/CN103874510A/zh active Pending
- 2012-08-24 ES ES12775123.8T patent/ES2648337T3/es active Active
- 2012-08-24 EP EP12775123.8A patent/EP2749291B1/en active Active
- 2012-08-24 KR KR1020147006186A patent/KR101857705B1/ko not_active Expired - Fee Related
- 2012-08-24 US US14/238,377 patent/US9549977B2/en active Active
- 2012-08-24 PH PH1/2014/500397A patent/PH12014500397B1/en unknown
- 2012-08-24 NO NO12775123A patent/NO2749291T3/no unknown
- 2012-08-24 SG SG11201400215SA patent/SG11201400215SA/en unknown
- 2012-08-24 PT PT127751238T patent/PT2749291T/pt unknown
- 2012-08-24 CA CA2844898A patent/CA2844898C/en active Active
- 2012-08-24 RU RU2014111465/15A patent/RU2580294C2/ru active
- 2012-08-24 BR BR112014004620-4A patent/BR112014004620B1/pt active IP Right Grant
-
2014
- 2014-02-14 CL CL2014000386A patent/CL2014000386A1/es unknown
- 2014-02-19 ZA ZA2014/01271A patent/ZA201401271B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201401271B (en) | 2015-04-29 |
| CA2844898A1 (en) | 2013-03-07 |
| WO2013029570A1 (es) | 2013-03-07 |
| CA2844898C (en) | 2021-06-22 |
| ES2648337T3 (es) | 2018-01-02 |
| JP6077541B2 (ja) | 2017-02-08 |
| MY191697A (en) | 2022-07-07 |
| AU2012303887B2 (en) | 2017-06-22 |
| MX351725B (es) | 2017-10-25 |
| KR101857705B1 (ko) | 2018-06-20 |
| CU20110167A7 (es) | 2013-06-28 |
| PH12014500397A1 (en) | 2014-04-14 |
| MX2014002214A (es) | 2014-04-30 |
| US20140294889A1 (en) | 2014-10-02 |
| CN103874510A (zh) | 2014-06-18 |
| US9549977B2 (en) | 2017-01-24 |
| KR20140064847A (ko) | 2014-05-28 |
| EP2749291A1 (en) | 2014-07-02 |
| CU24075B1 (es) | 2015-01-29 |
| CL2014000386A1 (es) | 2014-07-11 |
| EP2749291B1 (en) | 2017-10-18 |
| PH12014500397B1 (en) | 2018-09-12 |
| PT2749291T (pt) | 2017-11-24 |
| RU2014111465A (ru) | 2015-10-10 |
| RU2580294C2 (ru) | 2016-04-10 |
| JP2014524450A (ja) | 2014-09-22 |
| BR112014004620A2 (pt) | 2017-03-21 |
| NO2749291T3 (https=) | 2018-03-17 |
| SG11201400215SA (en) | 2014-09-26 |
| AU2012303887A1 (en) | 2014-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107250353B (zh) | 二价猪流感病毒疫苗 | |
| Chang et al. | Adjuvant activity of fish type I interferon shown in a virus DNA vaccination model | |
| CN113454102A (zh) | 非洲猪瘟疫苗 | |
| CN111447948B (zh) | 具有复制子颗粒和油佐剂的疫苗 | |
| CN102056941A (zh) | 编码白细胞介素-12的重组火鸡疱疹病毒 | |
| WO2022110099A1 (en) | Coronavirus vaccines and uses thereof | |
| ES2632429T3 (es) | Vacunas subunitarias de rotavirus y procedimientos para la fabricación y utilización de las mismas | |
| ES2347566T3 (es) | Inmunomodulador que comprende celulas enteras de bacterias tsukamurella. | |
| ES2648337T3 (es) | Uso del PACAP como adyuvante molecular para vacunas | |
| Martín-Martín et al. | Potential of the Escherichia coli LT (R192G/L211A) toxoid as a mucosal adjuvant for rainbow trout (Oncorhynchus mykiss) | |
| ES2549669T3 (es) | Propiedades de coadyuvancia y potenciación inmunitaria de productos naturales de Onchocerca volvulus | |
| US20220040289A1 (en) | Rabies Composition Comprising Pika Adjuvant | |
| PT1553979E (pt) | Proteína g de ihnv para estimulação imunitária | |
| CN115925823A (zh) | SARS-CoV-2编码蛋白来源的T细胞表位多肽FAFPFTIYSL及其应用 | |
| ES2798282T3 (es) | Una vacuna para usar contra la infección asintomática por Lawsonia en un cerdo | |
| EA009937B1 (ru) | Индукторы монопараиммунитета, основанные на ослабленных вирусах миксомы кролика | |
| El-shahedy et al. | Immunostimulant activity of levamisole to polyvalent FMD vaccine in buffaloes | |
| KR102089655B1 (ko) | 소 코로나바이러스 감염증 예방용 kwd20v-102 주의 약독화 생백신 조성물 | |
| KR20160044764A (ko) | 면역력을 증강시키는 아쥬반트를 포함하는 구제역 백신 조성물 및 이의 제조방법 | |
| Awais et al. | Covid-19 vaccines and their adequacy prospects in Pakistani population; A comparative review | |
| SIVASANKAR | HOST IMMUNE RESPONSES TO RANAVIRUS INFECTION IN MARINE AND FRESHWATER FISHES | |
| JP2013184922A (ja) | アジュバント、及び水産用ワクチン | |
| TW202203970A (zh) | 靶向冠狀病毒的IgY免疫球蛋白、其製備方法、及其使用方法 | |
| WO2019222864A1 (es) | Composicion inmunoestimulante comprendiendo microbacterias p. salmonis conjugado con derivados de heliotropium filifoliumun y al menos un diluyente; metodo y uso para inmunizar organismos acuaticos | |
| Baqar et al. | Modulation of immune responses to Bacterial vaccine antigens in Mice: Use of Cytokines as oral mucosal Adjuvants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2012, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2012, OBSERVADAS AS CONDICOES LEGAIS |